COVID-19 vaccine developed in Thailand can be stored in refrigerator for three months NatureMicrobiol
). It is therefore likely that dual vaccinations with ChulaCov19 vaccine may need a third booster dose, ideally with a second-generation vaccine.
Accessibility to effective COVID-19 vaccines, particularly mRNA vaccines, remains very limited in many LMICs, and the main goal of ChulaCov19 development is to be part of the solution to this problem. There are several challenges to overcome: clinical development to reach emergency use authorization , establishing large-scale manufacturing capacity, negotiation of expanding LNP-licensing territory, and the cost and long lead-time of raw materials.
The limitations of this study include the small sample size and dose-finding design. The exploratory comparative immunogenicity analyses with convalescent sera or Pfizer/BNT vaccinees’ sera are not head-to-head comparisons and are not free from bias. Convalescent sera were collected during the Delta wave in Thailand, and it is possible that human convalescent sera antibody responses are stronger against Delta than against WT.
In summary, we provide presumably the first evidence in humans that an mRNA vaccine expressing a prefusion non-stabilized spike protein is safe and highly immunogenic, similar to an approved mRNA vaccine, Pfizer/BNT, expressing a prefusion spike protein stabilized by the addition of a di-proline mutation. ChulaCov19 mRNA vaccine is well tolerated, elicited strong SARS-CoV-2-specific B- and T-cell immunogenicity, and is currently under phase 2 and later clinical development.
Danmark Seneste Nyt, Danmark Overskrifter
Similar News:Du kan også læse nyheder, der ligner denne, som vi har indsamlet fra andre nyhedskilder.
Excess deaths by sex and Age Group in the first two years of the COVID-19 pandemic in the United States - Health Care Management ScienceThe COVID-19 pandemic hastened hundreds of thousands of deaths in the United States. Many of these excess deaths are directly attributed to COVID-19, but others stem from the pandemic’s social, economic, and health care system disruptions. This study compares provisional mortality data for age and sex subgroups across different time windows, with and without COVID-19 deaths, and assesses whether mortality risks are returning to pre-pandemic levels. Using provisional mortality reports from the CDC, we compute mortality risks for 22 age and sex subgroups in 2021 and compare against 2015–2019 using odds ratios. We repeat this comparison for the first twelve full months of the COVID-19 pandemic in the United States (April 2020–March 2021) against the next twelve full months (April 2021–March 2022). Mortality risks for most subgroups were significantly higher in 2021 than in 2015–2019, both with and without deaths involving COVID-19. For ages 25–54, Year 2 (April 2021–March 2022) was more fatal than Year 1 (April 2020–March 2021), whereas total mortality risks for the 65 + age groups declined. Given so many displaced deaths in the first two years of the COVID-19 pandemic, mortality risks in the next few years may fall below pre-pandemic levels. Provisional mortality data suggest this is already happening for the 75 + age groups when excluding COVID-19 deaths.
Læs mere »
Long Covid: What's changed, and what we know nowThe ONS says more than a third of people with long Covid are thought to have acquired it during the Omicron wave
Læs mere »
Covid-19: New mum leaves Royal Papworth hospital after comaNicoleta Tuna, who was put in a coma after a C-section, is looking forward to her 'second life'.
Læs mere »